Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
Lorenza N C DezanetPatrick MiailhesCaroline Lascoux-CombeJulie ChasSarah MaylinAudrey GabassiHayette RougierConstance DelaugerreKarine LacombeAnders BoydPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
TDF-treated HIV-HBV coinfected individuals do not seem to benefit from comparable levels of liver fibrosis regression as in HBV mono-infection. Liver-related morbidity occurs mainly in those with fluctuating or consistently high fibrosis levels.
Keyphrases
- liver fibrosis
- hiv positive
- antiretroviral therapy
- men who have sex with men
- hepatitis b virus
- south africa
- hiv infected
- human immunodeficiency virus
- end stage renal disease
- hiv testing
- liver failure
- ejection fraction
- hepatitis c virus
- chronic kidney disease
- hiv aids
- prognostic factors
- peritoneal dialysis
- replacement therapy
- patient reported outcomes